After more than a year of pressure, a group of AIDS activists gained access to the R&D agreement central to a settlement between the U.S. government and Gilead Sciences over HIV prevention drug patents. The activists' verdict: the Biden administration missed what they called an "historic" opportunity to invest in HIV prevention and expand access to the drugs. A legal resolution, in their telling, is not the same as a policy win.
What the lawsuit was about
The settlement closed a case the Trump administration originally filed six years ago. The Centers for Disease Control and Prevention alleged Gilead infringed patents the agency held after helping fund academic research that later formed the basis for two HIV pills, Truvada and Descovy. The lawsuit alleged Gilead ignored the contributions of CDC scientists and overstated its own role in the drugs' development. It also alleged the company refused to sign a licensing agreement despite multiple government attempts to reach one, collecting hundreds of millions of dollars from taxpayer-funded research in the process.
Why activists are dissatisfied
For the AIDS advocacy community, receiving the R&D document is not the goal they were pursuing. The original complaint gave the U.S. government a concrete legal claim against one of the country's major HIV drug makers. That position, activists argue, warranted binding commitments on access to and pricing of HIV prevention tools. The settled terms, as they read them, do not deliver that.
The counterargument
The case for settlement rests on what litigation cannot guarantee. A patent dispute of this scale takes years to resolve and the outcome is never certain. An enforceable R&D agreement obtained through negotiation may be a more reliable result than a court judgment that could arrive years later and still be appealed. Patient advocates may find that argument unsatisfying. It reflects, however, the practical calculus federal agencies typically make when weighing the costs of prolonged litigation against the certainty of a negotiated deal.
On balance
The facts are not in dispute: CDC scientists helped develop the research behind Truvada and Descovy, Gilead collected hundreds of millions of dollars without signing a licensing agreement, and the government's legal case took six years to reach a conclusion. Whether the settlement terms match the weight of those underlying facts is the activists' real complaint. The line to watch is what the R&D agreement actually requires of Gilead and whether any of those obligations touch pricing or access.